Journal article
Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)
Abstract
To determine (1) the medium-term effect of rosiglitazone and glipizide on intra-stent neointima hyperplasia, (2) restenosis pattern as assessed by intra-vascular ultrasound (IVUS) and quantitative coronary angiography (QCA) in patients with T2DM and coronary artery disease. A total of 462 patients with T2DM were randomized to rosiglitazone or glipizide for up to 18 months in the APPROACH trial, and had evaluable baseline and follow-up IVUS …
Authors
García-García HM; Garg S; Brugaletta S; Morocutti G; Ratner RE; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Nesto RW
Journal
The International Journal of Cardiovascular Imaging, Vol. 28, No. 3, pp. 455–465
Publisher
Springer Nature
Publication Date
March 2012
DOI
10.1007/s10554-011-9836-z
ISSN
1569-5794
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAnalysis of VarianceAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary VesselsDiabetes Mellitus, Type 2Diabetic AngiopathiesDouble-Blind MethodDrug-Eluting StentsFemaleGlipizideHumansHyperplasiaHypoglycemic AgentsMaleMetalsMiddle AgedNeointimaPredictive Value of TestsProspective StudiesProsthesis DesignRosiglitazoneStentsThiazolidinedionesTime FactorsTreatment OutcomeUltrasonography, Interventional